Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo, dated February 16, 2004, reports the company's consolidated financial results for the fiscal year ended December 31, 2003. The filing also details the status of a public offer for Aventis shares announced in January 2004 and provides an outlook for 2004.
Key Financial Metrics
| Metric | 2003 Value | 2002 Value | Change |
|---|---|---|---|
| Consolidated Sales | €8,048 million | €7,448 million | +8.1% (reported) / +15.6% (comparable) |
| Gross Profit | €6,620 million | €6,070 million | +9.1% |
| Gross Margin | 82.3% | 81.5% | +0.8 percentage points |
| Operating Profit | €3,075 million | €2,614 million | +17.6% |
| Operating Margin | 38.2% | 35.1% | +3.1 percentage points |
| Net Income | €2,076 million | €1,759 million | +18.0% |
| Net Income (Adjusted*) | €2,069 million | €1,758 million | +17.7% |
| Earnings Per Share (Adjusted*) | €2.94 | €2.42 | +21.5% |
| Operating Cash Flow | €2,265 million | €1,676 million | +35.1% |
| Net Cash Position | €3,010 million | €2,672 million | +€338 million |
| Debt | €368 million | €416 million | -€48 million |
*Adjusted figures exclude exceptional items and goodwill amortization.
Material Changes vs. Prior Period
- Sales Growth: Consolidated sales grew 15.6% on a comparable basis, driven by a 20.4% increase in developed sales. Currency fluctuations had an unfavorable impact of 7.2 percentage points on reported growth.
- Profitability: Gross margin improved to 82.3% due to product mix, productivity, and royalties from Plavix and Avapro. Operating margin expanded to 38.2%.
- Expenses: R&D expenses rose 8.0% to €1,316 million (16.4% of sales), primarily due to clinical trials for Plavix, Aprovel/Avapro, and new candidates. Selling and general expenses increased 2.0% to €2,477 million, reflecting intensified marketing in the U.S.
- Joint Ventures: Net income from joint operations with Bristol-Myers Squibb increased 30.5% to €248 million, driven by higher profits from Plavix and Avapro in North America.
- Tax Rate: The effective tax rate increased to 33.9% from 28.9% in 2002, as the prior year benefited from abnormal write-backs and tax exemptions related to the Lorex joint venture.
- Share Buybacks: The company acquired 20.1 million shares for €1,017 million in 2003, reducing the average share count and contributing to EPS growth.
Guidance, Outlook, and Risks
2004 Outlook
- Sales: Management expects consolidated sales growth on a comparable basis to be similar to 2003 levels.
- EPS: Projected growth of around 15% (before exceptional items and goodwill amortization), assuming an exchange rate of 1.25 USD to 1 EUR.
- R&D: An acceleration in R&D expenses is anticipated.
- Sensitivity: EPS growth is sensitive to currency fluctuations, with a 1.2% impact for every 3-cent change in the euro/dollar rate.
R&D Highlights
- Phase III Success: Positive results for rimonabant (obesity/smoking cessation), dronedarone (atrial fibrillation), and Ambien CR (sleep induction).
- Phase IIb Success: Favorable results for saredutant (depression) and SR 121463 (SIADH), with Phase III trials planned for 2004.
- Termination: Development of tirapazamine in non-small cell lung cancer was terminated.
Contingencies and Risks
- Aventis Acquisition: A public offer for Aventis shares was announced on January 26, 2004. The dividend payment schedule is contingent on the closing of this offer.
- Forward-Looking Risks: Risks include the success of R&D programs, intellectual property protection, U.S. market expansion, and healthcare reimbursement/pricing reforms.
Investor Verification Checklist
- Verify the impact of the proposed Aventis acquisition on the company's capital structure and future debt levels.
- Confirm the timeline and regulatory approval status for the Phase III candidates (rimonabant, dronedarone, Ambien CR).
- Monitor the exchange rate sensitivity of the 2004 EPS guidance, particularly given the 1.2% sensitivity per 3-cent currency shift.
- Review the reconciliation of non-GAAP measures (comparable sales, adjusted EPS) to ensure consistency with GAAP reporting.
- Assess the sustainability of the gross margin expansion driven by royalties from Plavix and Avapro.